[A preclinical trial of iodoantipyrine safety].
作者信息
Saratikov A S, Novozheeva T P, Livshits N S, Burchenkova F I, Kadychagova N G, Akhmedzhanov R R, Bashirova L V, Eremina A A, Potapova G V
机构信息
Siberian Medical University, Tomsk, Russia.
出版信息
Eksp Klin Farmakol. 1998 Mar-Apr;61(2):57-9.
PMID:9621178
Abstract
Detailed preclinical study of the safety of the new antiviral agent iodantipyrine was conducted. In LD50 parameters it was found to be related to moderately toxic drugs. Long-term administration in doses of 50, 100, and 250 mg/kg did not cause any essential functional and structural disorders in the organs and systems of rats and dogs. Iodantipyrine does not possess mutagenic and allergenic properties and does not affect the reproductive function.
摘要
Zotero 插件